DA
RVNC

DCF Advisers’s Revance Therapeutics, Inc. RVNC Stock Holding History

DCF Advisers’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-19,417
Closed -$101K – 113
2024
Q3 		$101K Sell
19,417
-230,583
-92% -$1.15M 0.04% 91
2024
Q2 		$643K Sell
250,000
-13,372
-5% -$45.7K 0.33% 58
2024
Q1 		$1.3M Buy
263,372
+6,500
+3% +$38.5K 0.64% 37
2023
Q4 		$2.26M Buy
256,872
+230,372
+869% +$1.89M 1.23% 22
2023
Q3 		$304K Buy
+26,500
New +$509K 0.17% 76
2022
Q3 		– Sell
-12,000
Closed -$166K – 96
2022
Q2 		$166K Buy
+12,000
New +$185K 0.1% 71

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

DCF Advisers's RVNC Position: Q4 2024 in Review

DCF Advisers sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 19,417 shares — an estimated $101K sold.

DCF Advisers first reported a position in RVNC in Q2 2022 and held it in 6 quarters. The position peaked at $2.26M in Q4 2023. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • DCF Advisers reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • DCF Advisers sold 19,417 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $101K.
  • DCF Advisers first reported a position in Revance Therapeutics, Inc. in Q2 2022 and held it in 6 quarters.
  • DCF Advisers's Revance Therapeutics, Inc. position peaked at $2.26M in Q4 2023.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on DCF Advisers's 13F filing for Q4 2024, filed 11 Feb 2025.